Lauren R. Malakoff

Practice summary — Lauren R. Malakoff (Walsh Pizzi O'Reilly Falanga LLP, Newark, NJ)

Specialty / focus. Malakoff is an associate at Walsh Pizzi O'Reilly Falanga LLP whose firm bio centers on business/commercial litigation and labor & employment, with intellectual-property and patent litigation recognized since 2025 (Best Lawyers "Ones to Watch" for Litigation–Patent, among other areas). Her patent docket is concentrated in the District of New Jersey and is heavily pharmaceutical/biotech: Hatch-Waxman ANDA litigation (Intra-Cellular Therapies v. Sandoz), biologic drug-delivery patent disputes (Halozyme v. Merck over subcutaneous Keytruda and modified PH20 hyaluronidase enzyme technology), and a medical-device case (Boston Scientific v. Stryker, D.N.J.). She typically serves in a local- or supporting-counsel role on Walsh Pizzi matters led by Liza Walsh and Katelyn O'Reilly.

Side preference. Of five tracked appearances, four are plaintiff-side and one defendant-side — a predominantly patent-owner/plaintiff-side practice for operating life-sciences companies asserting patents against generic and branded rivals, rather than NPE/PAE monetization work.

Firm context & background. Malakoff has spent her entire legal career with Walsh Pizzi O'Reilly Falanga (summer associate 2019; associate since November 2022), preceded by judicial clerkships with New Jersey Supreme Court Justice Anne M. Patterson and U.S. District Judge Madeline Cox Arleo (D.N.J.). Admitted in New Jersey and New York (2022); J.D., cum laude, Seton Hall University School of Law (2020); B.A., cum laude, Villanova University (2015).

Notable matters and PTAB exposure. The headline matter is Halozyme, Inc. v. Merck Sharp & Dohme LLC, No. 2:25-cv-03179 (D.N.J.), where Walsh Pizzi represents Halozyme asserting 15 patents against Merck's subcutaneous Keytruda; the dispute has generated a parallel Merck PGR campaign against Halozyme patents (e.g., PGR2025-00006/-00009/-00039), and her tracked appearances include one PTAB matter (as of counsel) tied to that fight — though available sources do not show a broader, standalone IPR practice. Related public results in the overall dispute include a December 2025 German preliminary injunction for Halozyme and PTAB final written decisions in 2026 invalidating two Halozyme MDASE patents. She also entered appearances for plaintiff Intra-Cellular Therapies in an ANDA suit against Sandoz (2024) and is listed on the Boston Scientific v. Stryker device case, where the district court denied a preliminary injunction and the Federal Circuit affirmed in June 2026. As an associate/local counsel, case outcomes should be attributed to the Walsh Pizzi team rather than to her individually. No verdicts or settlements specifically tied to her personal advocacy were verified in web sources.